Gujarat Fluorochemicals Q2 FY27 Earnings Call: Revenue Jumps 45% YoY, Rs. 6,000 Crore Battery Funding Tied Up

Gujarat Fluorochemicals Ltd held its Q2 FY27 earnings call on November 03, 2026. Here's a quick read of what management said — performance, strategy, and the outlook ahead.

Strong Quarter Across the Board, Margin Steady at 27%

• Consolidated revenue of Rs.1,760 crore in Q2 FY27 — up 45% YoY and 11% QoQ; EBITDA of Rs.473 crore (+32% YoY, +11% QoQ) with margin steady at 27%.
• PAT of Rs.240 crore — +42% YoY and +10% QoQ, with the chemical segment's PAT growth outpacing revenue/EBITDA on margin expansion.
• Chemical segment revenue of Rs.1,723 crore (+42% YoY) — EBITDA Rs.505 crore (+33% YoY, +10% QoQ) and PAT Rs.290 crore (+46% YoY) in Q2 FY27.
• Bulk chemicals was the laggard — revenue of Rs.151 crore, down 5% YoY and 8% QoQ, on lower caustic soda prices and higher captive chloromethanes consumption for R32 production.
• Macro caveats flagged by management — Europe conflict, Gulf developments, evolving trade/tariff policies, financial and bond market volatility, and climate risks, though India has maintained growth momentum on strong domestic fundamentals.

Fluoropolymers Beat Guidance; R32 and R134A Ramp on Track

• Fluoropolymers revenue of Rs.931 crore in Q2 FY27, +22% YoY (vs Rs.764 crore in Q2 FY26) and +2% QoQ, exceeding the company's prior FY27 guidance of 17-20% annual growth; management remains confident of sustaining this trajectory.
• Growth led by FKM (automotive) and PFA/modified PTFE (semiconductors, data centers) — driven by both volume and mix shift toward higher-value applications; focus now on debottlenecking, with additional growth capex planned over the next one year (FY 2027-2028).
• Management expects fluoropolymer momentum to continue for the next couple of years (FY 2027-2028 onward) — citing EV, semiconductor and data center traction, with green hydrogen expected to follow; the committed 17-20% growth guidance was reiterated (period unspecified), with capex planned to follow growth.
• Fluorochemicals revenue of Rs.607 crore, +135% YoY (vs Rs.258 crore in Q2 FY26) and +33% QoQ, driven by refrigerants, particularly R32; initial R32 capacity expected to reach full utilization by end of Q3 FY 2026-2027.
• R134A project on track to commence production by Q4 FY27 — completing a portfolio of R22, R32, R125, R410 and R134A; refrigerant demand and pricing stable in the near term.

Transition from Qualification to Commercialization; Salt Leads Revenue

• LiPF6 ramping well with sales to 5 major global electrolyte players — most volumes under volume-binding, formula-based contracts (linked to lithium prices) with little spot sales; contracts generally annual or longer, with volumes bound at least for FY 2027-2028 and some extending beyond.
• LiPF6 prices in China fell from 1,50,000 yuan to ~100,000 yuan over the last month — management attributes the decline to falling lithium prices and states it is largely a pass-through, so margins remain protected.
• Full utilization of expanded LiPF6 capacity expected by Q1 FY 2027-2028 — with planned salt capacities close to full utilization by Q1-Q2 FY 2027-2028, making salt the biggest initial revenue driver.
• LFP (CAM) samples in customer qualification programs globally, including India — the large-capacity Oman plan has been put on hold and shifted to India; significant new LFP capacity expected by Q3 FY 2027-2028, with revenue impact only toward end of FY 2027-2028 or beginning of FY 2028-2029.
• PVDF and PTFE grades at advanced qualification stages — across wet and next-generation dry electrode applications, with strong US/Europe engagement; commercial supplies under long-term agreements expected from Q4 FY27.
• Domestic electrolyte demand expected to ramp from the middle of FY 2027-2028 — with P&L reflection toward end of FY 2027-2028; the company is engaged with 3 cell makers currently producing in India (EV and ESS), with samples at an early evaluation stage, not yet line validation. India battery plants announced are running behind schedule, and India battery production (GWh) remains at very low levels.
• Revenue sequence confirmed by management: salts → LFP → electrolyte → anode — the anode project has been deliberately slowed/put on hold (timeline unspecified); FY 2027-2028 battery chemicals revenue expected to be driven mostly by exports.

Rs.6,000 Crore Battery Program: Funding Largely Tied Up, Execution Slipping

• FY27 capex guidance of ~Rs.3,000+ crore — ~Rs.2,100 crore for battery materials and Rs.800 crore for the core business (the Rs.800 crore already includes fluoropolymer investments, per CEO Dr. Bir Kapoor); the core capex is at almost half-point execution at the FY27 half-way mark.
• Battery materials capex is slightly behind plan — with the Oman shift to India, execution has slipped by roughly 1.5 quarters, so FY27 battery spend will spill over into FY28 (FY 2027-2028).
• Battery materials gross block of ~Rs.2,000 crore at FY26 — Group CFO guided it to reach close to Rs.4,000 crore by end of FY27 and ~Rs.6,000 crore by FY28; ~Rs.3,600 crore of the Rs.6,000 crore is yet to be deployed, with sources-of-funds visibility for the next five to six quarters.
• ~Rs.3,200 crore of the Rs.6,000 crore already raised as of the Q2 FY27 call — ~Rs.2,300 crore equity (IFC ~Rs.500 crore, an earlier round ~Rs.1,000 crore, GFL ~Rs.800 crore) plus Rs.900 crore bank debt (Sumitomo Bank Rs.600 crore, ICICI Bank Rs.300 crore), per Group CFO Akhil Jindal; management estimates another Rs.500-700 crore of equity over the next 3-4 months (by ~Q4 FY 2026-2027).
• Target end-state mix for the Rs.6,000 crore program — ~Rs.1,500 crore loans, ~Rs.3,000-3,500 crore total equity, ~Rs.1,000 crore internal accruals; management reiterated that no put option or backstop has been provided by the parent or promoters.
• Battery materials guidance held at 2x asset turns and 25% EBITDA margin (period unspecified) — no upgrade indicated when asked whether the project's shift to India could drive upside.

Dry-Electrode PTFE Upside; Electronic Chemicals at Conceptual Stage

• Dry electrode (solvent-free cathode) technology at an advanced stage of commercialization globally — several GFL PTFE grades are at an advanced stage of trials; management sees a "very huge upside" for the PTFE business as more battery makers move to dry electrode systems, citing no solvent evaporation, no solvent recovery, and environmental benefits.
• One or two battery manufacturers are very close to dry-electrode commercialization — per management, as of Q2 FY 2026-2027; GFL is talking to a few battery manufacturers on dry electrode and is "very optimistic" adoption happens "very soon".
• Electronic chemicals plant (location referenced as Jani Yadra) at a very early stage of discussion and conceptualization — management declined to disclose the product or capex, stating it has not mentioned any of the chemicals the analyst named (WF6, C4F6, NF3, F2N2, PFPE); details to be shared in the next few quarters (from Q3 FY 2026-2027 onward).
• Government focus on semiconductor/electronic chemicals cited by management — management noted "a very strong focus from the government to promote the semiconductor/electronic chemicals sector" and views it as a strong area for GFL given its fluorochemicals expertise; the analyst observed only one or two Japanese players operate in this space, which management agreed would be good for India and the company.
• LFP backward integration into iron phosphate (FP) planned — timing deliberately aligned with the LFP sales ramp-up (period unspecified); management declined to quantify the cost reduction from in-house FP, stating backward integration is a standalone project that should have its own returns.

Positive Margin Bias, But Ramp-Up Timing Is the Key Risk

• Management closed with a positive bias on margins — no specific margin figure was quantified in the closing remarks; other segments were described as continuing to do exceedingly well while battery materials develops.
• Battery materials framed as a long-term strategic initiative — management believes the segment will yield substantial value in the long run, citing long approval cycles and gestation periods as critical entry barriers it has crossed.
• Business model requires committing large capex before revenue begins — management noted revenues are tied to end-product ramp-up, where the company has seen some delays; pace of ramp-up is linked to customer qualification timelines, commercial approvals, and capacity ramp-up.
• Strategy anchored on three pillars — strengthening core fluoropolymers, expanding the fluorochemicals portfolio, and building a scalable advanced battery materials platform as a future growth engine.